John I. Wurzelmann

921 total citations
20 papers, 683 citations indexed

About

John I. Wurzelmann is a scholar working on Public Health, Environmental and Occupational Health, Ophthalmology and Epidemiology. According to data from OpenAlex, John I. Wurzelmann has authored 20 papers receiving a total of 683 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Public Health, Environmental and Occupational Health, 6 papers in Ophthalmology and 5 papers in Epidemiology. Recurrent topics in John I. Wurzelmann's work include Retinal Diseases and Treatments (5 papers), Retinal Imaging and Analysis (5 papers) and Inflammatory Bowel Disease (3 papers). John I. Wurzelmann is often cited by papers focused on Retinal Diseases and Treatments (5 papers), Retinal Imaging and Analysis (5 papers) and Inflammatory Bowel Disease (3 papers). John I. Wurzelmann collaborates with scholars based in United States, United Kingdom and Switzerland. John I. Wurzelmann's co-authors include Cynthia M. Lyles, Robert S. Sandler, Robert S. Sandier, Amy Pierce, Wendy J. Carman, Andrew T. McAfee, Suzanne F. Cook, John T. Woosley, Sharon C. Murray and Mark W. Russo and has published in prestigious journals such as American Journal of Epidemiology, Ophthalmology and American Journal of Ophthalmology.

In The Last Decade

John I. Wurzelmann

20 papers receiving 662 citations

Peers

Countries citing papers authored by John I. Wurzelmann

Since Specialization

Citations

This map shows the geographic impact of John I. Wurzelmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John I. Wurzelmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John I. Wurzelmann more than expected).

Fields of papers citing papers by John I. Wurzelmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John I. Wurzelmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John I. Wurzelmann. The network helps show where John I. Wurzelmann may publish in the future.

Co-authorship network of co-authors of John I. Wurzelmann

This figure shows the co-authorship network connecting the top 25 collaborators of John I. Wurzelmann. A scholar is included among the top collaborators of John I. Wurzelmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John I. Wurzelmann. John I. Wurzelmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Epidemiology of opioid pharmacy claims in the United States 2018 ·Journal of Opioid Management ·(unknown), Barry Sampson, (unknown), John I. Wurzelmann, (unknown)	6
2	Patient-Reported Visual Function in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (AMD): Baseline Characteristics of the BAM114341 Cohort 2015 ·Investigative Ophthalmology & Visual Science ·Fang Wang, (unknown), John I. Wurzelmann, (unknown), Michael R. Schwartz, (unknown)	1
3	A systematic review and meta-analysis to compare the efficacy of acyclovir 3% ophthalmic ointment to idoxuridine in curing herpetic keratitis by Day 7 of treatment 2015 ·BMC Ophthalmology ·(unknown), Gengqian Cai, Michael Fries, David Kleinman, Megan McLaughlin, (unknown), John I. Wurzelmann, (unknown)	6
4	Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Diabetic Macular Edema 2015 ·Ophthalmology ·Giovanni Staurenghi, Ye Li, Mindy Magee, Ronald P. Danis, John I. Wurzelmann, Peter Adamson, Megan McLaughlin	37
5	SNPs Associated with Complement Factor I Do Not Predict 4-month Lesion Growth Rate in Geographic Atrophy 2015 ·John I. Wurzelmann, Francisco J. López, (unknown), (unknown), Michael R. Schwartz, Astrid Yeo, Lingkang Huang, Amitha Domalpally, Ronald P. Danis, (unknown)	1
6	CLINICAL EVALUATION OF PAZOPANIB EYE DROPS IN HEALTHY SUBJECTS AND IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION 2014 ·Retina ·Rishi P. Singh, John I. Wurzelmann, Ye Li, Linda S. Henderson, Mohammad Sharif Hossain, (unknown), (unknown)	20
7	Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration 2014 ·Ophthalmology ·Karl G. Csaky, Pravin U. Dugel, Amy Pierce, Michael Fries, (unknown), Ronald P. Danis, John I. Wurzelmann, Chun‐Fang Xu, Mohammad Sharif Hossain, (unknown)	59
8	Predictive Models of Choroidal Neovascularization and Geographic Atrophy Incidence Applied to Clinical Trial Design 2012 ·American Journal of Ophthalmology ·Linda McCarthy, Paul J. Newcombe, John C. Whittaker, John I. Wurzelmann, Michael Fries, (unknown), Gengqian Cai, Sandra W. Stinnett, (unknown), Chun‐Fang Xu	12
9	A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/012) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain 2011 ·Journal of Pain ·Jan‐Peter Jansen, Daniel Lorch, (unknown), Ben Lasko, Kai Hermanns, C. Kleoudis, Jerry Snidow, Amy Pierce, John I. Wurzelmann, Eric Mortensen	59
10	A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/013) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain 2011 ·Journal of Pain ·Gordon Irving, (unknown), Brian Ramjattan, Michael J. Cousins, Richard Rauck, Egilius L.H. Spierings, C. Kleoudis, Jerry Snidow, Amy Pierce, John I. Wurzelmann, Eric Mortensen	59
11	Coronary heart disease outcomes among chronic opioid and cyclooxygenase‐2 users compared with a general population cohort 2011 ·Pharmacoepidemiology and Drug Safety ·Wendy J. Carman, (unknown), Suzanne F. Cook, John I. Wurzelmann, Andrew T. McAfee	91
12	Enhancing enrollment in palliative care trials: key insights from a randomized, placebo-controlled study. 2010 ·PubMed ·Amy P. Abernethy, David C. Currow, John I. Wurzelmann, (unknown), Janet Bull, (unknown), (unknown), Amy Pierce, Jerry Snidow	19
13	Ethical Issues, Safety, and Data Integrity in Clinical Trials 2005 ·Inflammatory Bowel Diseases ·William J. Tremaine, (unknown), Kim L. Isaacs, Kathleen J. Motil, Patricia R. Robuck, John I. Wurzelmann	2
14	Understanding the Drug Development Process 2005 ·Inflammatory Bowel Diseases ·Patricia R. Robuck, John I. Wurzelmann	11
15	Plasma selenium levels and the risk of colorectal adenomas 1997 ·Nutrition and Cancer ·Mark W. Russo, Sharon C. Murray, John I. Wurzelmann, John T. Woosley, Robert S. Sandier	71
16	Stimulus 1995 ·Journal of Clinical Gastroenterology ·Robert S. Sandier, Glenn M. Eisen, Andrew H. Talal, John I. Wurzelmann	10
17	Childhood infections and the risk of inflammatory bowel disease 1994 ·Digestive Diseases and Sciences ·John I. Wurzelmann, Cynthia M. Lyles, Robert S. Sandler	125
18	Childhood Exposure to Environmental Tobacco Smoke and the Risk of Ulcerative Colitis 1992 ·American Journal of Epidemiology ·Robert S. Sandier, Dale P. Sandler, (unknown), John I. Wurzelmann	49
19	Oral Contraceptive Use and the Risk of Inflammatory Bowel Disease 1992 ·Epidemiology ·Robert S. Sandler, John I. Wurzelmann, Cynthia M. Lyles	34
20	Neuropsychological Effects of Antihypertensive Drugs 1987 ·Cardiology Clinics ·John I. Wurzelmann, William H. Frishman, Miriam K. Aronson, David Masur, Wee Lock Ooi	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact